Abstract
The unprecedented advances in cancer genetics and genomics have transformed the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, breast, and gynecologic malignancies among others. In sharp contrast, until recently, molecular biomarkers were noticeably absent from the management algorithms of urologic malignancies, including bladder cancer. Integrated genomic analyses of bladder cancer have led to a novel molecular taxonomy of muscle-invasive carcinoma and the identification of predictive markers for newly elucidated targets of therapy. Clinical trials to evaluate these strategies are finally being launched and will hopefully facilitate their adoption in routine practice. The following is an overview of the molecular pathways involved in bladder cancer oncogenesis with a focus on promising candidate biomarkers that may soon make their transition to the realm of clinical management of urothelial carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Suggested Reading
Al-Ahmadie H, Netto GJ. Updates on the genomics of bladder cancer and novel molecular taxonomy. Adv Anat Pathol. 2020;27:36–43.
Al-Ahmadie H, Netto GJ. Molecular pathology of urothelial carcinoma. Surg Pathol Clin. 2021;14:403–14.
Al-Obaidy KI, Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021;74:491–5.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.
Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:2903–10.
Cheng L, Davidson DD, Maclennan GT, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther. 2010;10:865–80.
Cheng L, Zhang S, Alexander R, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011a;35:e34–46.
Cheng L, Zhang S, Maclennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2011b;42:455–81.
Cheng L, Lopez-Beltran A, Bostwick DG. Bladder pathology. Wiley-Blackwell: Hoboken, NJ; 2012.
Cheng L, Davison DD, Adams J, et al. Biomarkers in badder cancer: translational and clinical implications. Crit Rev Oncol Hematol. 2014;89:73–111.
Cheng L, Zhang S, Wang L, et al. Fluorescence in situ hybridization in surgical pathology: principles and applications. J Pathol Clin Res. 2017;3:73–99.
Cheng L, Zhang S, Wang M, et al. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Hum Pathol. 2023;133:56–75.
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–65.
Damrauer JS, Beckabir W, Klomp J, et al. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun. 2022;13:6658.
Flaig TW, Tangen CM, Daneshmand S, et al. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021;27:2435–41.
Flaig TW, Spiess PE, Abern M, et al. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022;20:866–78.
Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial. J Clin Oncol. 2007;25:2218–24.
Kamoun A, de Reynies A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420–33.
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
Kouba EJ, Cheng L. Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis and treatment. JAMA Oncol. 2017;3:1570–8.
Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70:3463–72.
Lindskrog SV, Prip F, Lamy P, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.
Lopez-Beltran A, Cimadamore A, Montironi R, Cheng L. Molecular pathology of urothelial carcinoma. Hum Pathol. 2021;113:67–83.
Lotan Y, de Jong JJ, Liu VYT, et al. Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy. J Urol. 2022;207:541–50.
Magers MJ, Cheng L. Practical molecular testing in a clinical genitourinary service. Arch Pathol Lab Med. 2020;144:277–89.
Netto GJ. Molecular diagnostics in urologic malignancies: a work in progress. Arch Pathol Lab Med. 2011;135:610–21.
Netto GJ, Cheng L. Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med. 2012;36:372–90.
Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology. 2010;42:384–94.
Netto GJ, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469–82.
Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2020;21:105–20.
Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–56.
Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23:248–5.
Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81:523–32.
Sonpavde GP, Mouw KW, Mossanen M. Therapy for muscle-invasive urothelial carcinoma: controversies and dilemmas. J Clin Oncol. 2022;40:1275–80.
Thomas J, Sonpavde G. Molecularly targeted therapy towards genetic alterations in advanced bladder cancer. Cancers (Basel). 2022;14:1795.
Tran L, Xiao JF, Agarwal N, et al. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104–21.
van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912–21.
van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58:433–41.
Warrick JI, Knowles MA, Yves A, et al. Report from the International Society of Urological Pathology (ISUP) Consultation Conference on molecular pathology of urogenital cancers. II. Molecular pathology of bladder cancer: progress and challenges. Am J Surg Pathol. 2020;44:e30–46.
Yang Y, Miller CR, Lopez-Beltran A, et al. Liquid biopsies in the management of bladder cancer: next-generation biomarkers for diagnosis, surveillance and treatment response prediction. Crit Rev Oncog. 2017;22:389–401.
Yang Y, Kaimakliotis HZ, Williamson SR, et al. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. Urol Oncol. 2020;38:449–58.
Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV 201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Netto, G.J., Cheng, L. (2023). Molecular Pathology of Urinary Bladder Tumors. In: Cheng, L., Netto, G.J., Eble, J.N. (eds) Molecular Surgical Pathology. Springer, Cham. https://doi.org/10.1007/978-3-031-35118-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-031-35118-1_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-35117-4
Online ISBN: 978-3-031-35118-1
eBook Packages: MedicineMedicine (R0)